Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Research & Development: 2010-2025

Historic Research & Development for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to $21.0 million.

  • Ligand Pharmaceuticals' Research & Development rose 270.38% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.1 million, marking a year-over-year increase of 265.07%. This contributed to the annual value of $21.4 million for FY2024, which is 12.68% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Research & Development stood at $21.0 million, which was up 220.07% from $6.6 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Research & Development high stood at $50.1 million for Q1 2025, and its period low was $4.4 million during Q4 2024.
  • Moreover, its 3-year median value for Research & Development was $6.0 million (2024), whereas its average is $11.2 million.
  • In the last 5 years, Ligand Pharmaceuticals' Research & Development crashed by 42.19% in 2021 and then surged by 738.80% in 2025.
  • Ligand Pharmaceuticals' Research & Development (Quarterly) stood at $8.1 million in 2021, then climbed by 12.89% to $9.2 million in 2022, then plummeted by 40.33% to $5.5 million in 2023, then fell by 19.37% to $4.4 million in 2024, then spiked by 270.38% to $21.0 million in 2025.
  • Its Research & Development stands at $21.0 million for Q3 2025, versus $6.6 million for Q2 2025 and $50.1 million for Q1 2025.